In short, aggregation is the undertaking of creating a hierarchic relationship between distinctive identifiers assigned to packaging containers. Companies have been complying with Serialization guidelines for a while now, i.e., the process of labelling each individual unit of medicine with a unique identifier so it can be tracked through the supply chain. However, individual units are not sent through the supply chain piecemeal – they are transported and distributed as part of larger batches, bundles, cases or pallets. Aggregation refers to labelling each of these larger units with their own unique identifier to ease the process of tracking the individual units within the box. Thus, it is meant to ease the process of serialization and greatly enhance transparency in the supply chain. For example, you don’t need to open a case to get the identifiers of all individual unit-level codes inside, or when you unpack a pallet you can easily tell if there are units missing.
Even though aggregation is not required under EU FMD at the moment, it is certainly on the horizon for most markets, if not already implemented. For example, the DSCSA (Drug Supply Chain Security Act) in the USA intends to implement full-scale aggregation by 2023. Russia has already implemented aggregation on some levels. Thus, when it comes to regulations around aggregation, it is not a question of if, it is a question of when. Implementing aggregation-forward practices makes sense for companies from a commercial point of view, because it not only does it help with serialization, it also makes the distribution chain and stock management processes more efficient. It adds visibility in the supply chain by providing clarity without having to unpack pallets and bundles as they move between manufacturers, wholesalers, retailers and other third-party logistics vendors.
Logic follows that there will costs involved in the implementation of aggregation across a pharmaceutical company’s supply chain. However, having serialization processes already incorporated will mostly help mitigate these costs.
While most current regulations about the traceability of pharmaceuticals are set in place around serialization and not aggregation, it is a critical component of track and trace, both internally and externally. It is the next logical step, and it is also essentially a business opportunity, given how much it elevates the operating efficiency of your business. Serialization and aggregation are now closely intertwined, and having the proper processes and equipment to manage these complicated procedures is a large step toward total pharmaceutical traceability.
Cosmotrace’s team of experienced professionals have spent years working with every part of the pharmaceutical supply chain. Contact us today to find out how we can help you implement aggregation into your supply chain:
Tel: +44 203 097 1597
About CosmoTrace
CosmoTrace was formed by an expert, experienced team that has since worked extensively with every part of the pharmaceutical supply chain from manufacturing through to final distribution. As Serialization Consulting Experts, our focus is on delivering the absolute best serialization support by offering long-term serialization and sustainability strategies and providing forward-thinking industry solutions.
We offer premium support and services that can help your business with serialization implementation. Our team of experts ensure that you are up to date with all global traceability regulations and will help in creating a successful long-term serialization strategy.
To learn more about CosmoTrace visit www.cosmotrace.com. Follow us on LinkedIn and Twitter for Serialization and industry related updates.